[Sickle cell disease in French Guiana: assessing 30 years of neonatal screening (1992-2021)].

Medecine tropicale et sante internationale Pub Date : 2024-02-13 eCollection Date: 2024-03-31 DOI:10.48327/mtsi.v4i1.2024.488
Narcisse Elenga, Vathanaksambath Ro, Joddy Mafema Missindu, Noelis Thomas Boizan, Tania Vaz, Aude Lucarelli, Marie Élise Armoudon-Fleret, Solange Buendé
{"title":"[Sickle cell disease in French Guiana: assessing 30 years of neonatal screening (1992-2021)].","authors":"Narcisse Elenga, Vathanaksambath Ro, Joddy Mafema Missindu, Noelis Thomas Boizan, Tania Vaz, Aude Lucarelli, Marie Élise Armoudon-Fleret, Solange Buendé","doi":"10.48327/mtsi.v4i1.2024.488","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sickle cell disease is one of the most common genetic diseases in France. In French Guiana, neonatal screening was introduced in 1992, at the same time as other screening programs for childhood diseases. The aim of this study is to describe the organization of newborn screening for sickle cell disease in French Guiana.</p><p><strong>Materials and methods: </strong>We used several data sources: data collected from hospital records since 2005, activity reports from the national neonatal screening program and data from screening campaigns organized by the Drepaguyane association between 2010 and 2021 on 1,300 subjects. Blood samples from newborns are collected by capillary or venous sampling and absorbed on blotting paper (Guthrie) at the same time as those for other neonatal screenings. The dried papers are sent to the inter-regional laboratory in Lille, for further processing. In Saint-Laurent-du-Maroni, in order to reduce the proportion of people lost to follow-up, a double screening is carried out and the results are returned before discharge from the maternity hospital. All data were entered into an anonymous Excel file. The data were analyzed using STATA software.</p><p><strong>Results: </strong>Among the 175,593 screened neonates between 1992 and 2021, screening detected 823 infants with sickle cell disease and 17,950 heterozygotes. Sickle cell genotypes include 493 SS (60%), 302 SC (37%) and 28 S-Beta-thalassemia (3%). The incidence of sickle cell disease was 1/213, 95% CI [1/236-1/204], and that of heterozygotes 1/10, IC 95% [1/12-1/8]. The majority of these children (52%) were from the Maroni region. The delay between screening and test results was 7 days. Only pathological results (homozygous, heterozygous) were communicated to parents and/or the attending physician by post. These data confirm the upward trend in the number of children screened for sickle cell disease in French Guiana. Data from screening campaigns organized by the Drepaguyane association have enabled to describe the distribution of the various abnormal hemoglobin fractions, and to confirm that HbS is more frequent in Western French Guiana. In Cayenne, in 2021, the active file comprised 699 patients, including 266 children under 18 years old.</p><p><strong>Discussion and conclusion: </strong>This study provides valuable data on 30 years of neonatal screening for sickle cell disease in French Guiana, and on the evolution of sickle cell disease patients. It confirms that French Guiana is the French territory with the highest incidence of sickle cell disease. This incidence continues to rise over time. The study reveals the improvement in the organization of sickle cell disease management in French Guiana between 1992, when screening was introduced, and the present day. It highlights the role of patient associations in the fight against this disease, by organizing awareness and screening campaigns. These data will be used to guide public health policies in the pursuit of improved care and primary prevention.</p>","PeriodicalId":101416,"journal":{"name":"Medecine tropicale et sante internationale","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11151905/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medecine tropicale et sante internationale","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48327/mtsi.v4i1.2024.488","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/31 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Sickle cell disease is one of the most common genetic diseases in France. In French Guiana, neonatal screening was introduced in 1992, at the same time as other screening programs for childhood diseases. The aim of this study is to describe the organization of newborn screening for sickle cell disease in French Guiana.

Materials and methods: We used several data sources: data collected from hospital records since 2005, activity reports from the national neonatal screening program and data from screening campaigns organized by the Drepaguyane association between 2010 and 2021 on 1,300 subjects. Blood samples from newborns are collected by capillary or venous sampling and absorbed on blotting paper (Guthrie) at the same time as those for other neonatal screenings. The dried papers are sent to the inter-regional laboratory in Lille, for further processing. In Saint-Laurent-du-Maroni, in order to reduce the proportion of people lost to follow-up, a double screening is carried out and the results are returned before discharge from the maternity hospital. All data were entered into an anonymous Excel file. The data were analyzed using STATA software.

Results: Among the 175,593 screened neonates between 1992 and 2021, screening detected 823 infants with sickle cell disease and 17,950 heterozygotes. Sickle cell genotypes include 493 SS (60%), 302 SC (37%) and 28 S-Beta-thalassemia (3%). The incidence of sickle cell disease was 1/213, 95% CI [1/236-1/204], and that of heterozygotes 1/10, IC 95% [1/12-1/8]. The majority of these children (52%) were from the Maroni region. The delay between screening and test results was 7 days. Only pathological results (homozygous, heterozygous) were communicated to parents and/or the attending physician by post. These data confirm the upward trend in the number of children screened for sickle cell disease in French Guiana. Data from screening campaigns organized by the Drepaguyane association have enabled to describe the distribution of the various abnormal hemoglobin fractions, and to confirm that HbS is more frequent in Western French Guiana. In Cayenne, in 2021, the active file comprised 699 patients, including 266 children under 18 years old.

Discussion and conclusion: This study provides valuable data on 30 years of neonatal screening for sickle cell disease in French Guiana, and on the evolution of sickle cell disease patients. It confirms that French Guiana is the French territory with the highest incidence of sickle cell disease. This incidence continues to rise over time. The study reveals the improvement in the organization of sickle cell disease management in French Guiana between 1992, when screening was introduced, and the present day. It highlights the role of patient associations in the fight against this disease, by organizing awareness and screening campaigns. These data will be used to guide public health policies in the pursuit of improved care and primary prevention.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[法属圭亚那镰状细胞病:新生儿筛查 30 年评估(1992-2021 年)]。
背景:镰状细胞病是法国最常见的遗传病之一:镰状细胞病是法国最常见的遗传病之一。法属圭亚那于 1992 年开始实施新生儿筛查,与其他儿童疾病筛查计划同时进行。本研究旨在描述法属圭亚那新生儿镰状细胞病筛查的组织情况:我们使用了多种数据来源:自 2005 年以来从医院记录中收集的数据、国家新生儿筛查计划的活动报告以及 Drepaguyane 协会在 2010 年至 2021 年期间组织的筛查活动中收集的 1,300 名受试者的数据。新生儿血液样本通过毛细血管或静脉采样采集,并与其他新生儿筛查样本同时吸附在吸墨纸(Guthrie)上。干燥后的纸张被送往里尔的地区间实验室进行进一步处理。在圣洛朗-杜马洛尼,为了减少失去随访的比例,会进行双重筛查,并在产科医院出院前返回筛查结果。所有数据均输入匿名 Excel 文件。数据使用 STATA 软件进行分析:在 1992 年至 2021 年期间筛查的 175,593 名新生儿中,筛查出 823 名镰状细胞病婴儿和 17,950 名杂合型婴儿。镰状细胞基因型包括 493 个 SS(60%)、302 个 SC(37%)和 28 个 S-Beta 地中海贫血(3%)。镰状细胞病的发病率为 1/213,95% CI [1/236-1/204];杂合子的发病率为 1/10,IC 95% [1/12-1/8]。这些儿童中的大多数(52%)来自马罗尼地区。筛查与检测结果之间的延迟时间为 7 天。只有病理结果(同卵双生、异卵双生)才会邮寄给家长和/或主治医生。这些数据证实,法属圭亚那接受镰状细胞病筛查的儿童人数呈上升趋势。德雷帕瓜尼亚协会(Drepaguyane)组织的筛查活动数据有助于描述各种异常血红蛋白分数的分布情况,并证实 HbS 在法属圭亚那西部更为常见。2021 年,在卡宴,有效档案中有 699 名患者,其中包括 266 名 18 岁以下的儿童:这项研究提供了法属圭亚那 30 年来新生儿镰状细胞病筛查以及镰状细胞病患者演变的宝贵数据。研究证实,法属圭亚那是法国镰状细胞病发病率最高的地区。随着时间的推移,发病率还在继续上升。研究显示,从 1992 年开始筛查镰状细胞病到现在,法属圭亚那的镰状细胞病管理组织有所改善。研究强调了患者协会通过组织宣传和筛查活动在抗击镰状细胞病方面所发挥的作用。这些数据将用于指导公共卫生政策,以改善护理和初级预防。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
0
期刊最新文献
[2nd Mayotte en Santé conference - Disadvantaged territories - September 18-20, 2023 - Mayotte]. [Auricular and periauricular pathologies in the ENT department of Sylvanus Olympio Teaching Hospital in Lome (Togo)]. [SFMTSI Congress - Health in the Mediterranean Pathologies - Migrations - Environment 22-24 May 2024 Saint-Raphaël, France]. [Evaluation of molecular diagnosis of tuberculosis and resistance to rifampicin with GeneXpert® MTB/RIF in Algeria]. [XXVIIIth Actualités du Pharo. Health at work, between family and company: what are the issues for Southern countries? 4-6 October 2023 Marseille, France].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1